drugset
drugset / Trial / NCT00802126

Intravitreal Bevacizumab and Low Fluence Photodynamic Therapy

NCT00802126 ↗

Phase 1 Completed 16 enrolled University of Campania Luigi Vanvitelli
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to report the treatment effect and safety of combined intravitreal bevacizumab (IVB) and photodynamic therapy (PDT) with verteporfin using a reduced (RF) light fluence rate, in choroidal neovascularization (CNV) secondary to pathologic myopia.

Timeline

Start
2007-11
Primary completion
2008-12
Completion
2009-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Bevacizumab Monoclonal antibody 1.25 mg Intravitreal
Subject Verteporfin Other / unclassified — —

Indications

myopia